Senescent cells: a therapeutic target for cardiovascular disease
Bennett G. Childs,1 Hu Li,2 and Jan M. van Deursen1,3
1Department of Biochemistry and Molecular Biology,
2Department of Molecular Pharmacology and Experimental Therapeutics, and
3Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Address correspondence to: Jan M. van Deursen, 200 1st St. SW, Rochester MN 55902, USA. Phone: 507.284.8417; Email: vandeursen.jan@mayo.edu.
Find articles by Childs, B. in: JCI | PubMed | Google Scholar
1Department of Biochemistry and Molecular Biology,
2Department of Molecular Pharmacology and Experimental Therapeutics, and
3Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Address correspondence to: Jan M. van Deursen, 200 1st St. SW, Rochester MN 55902, USA. Phone: 507.284.8417; Email: vandeursen.jan@mayo.edu.
Find articles by
Li, H.
in:
JCI
|
PubMed
|
Google Scholar
|
1Department of Biochemistry and Molecular Biology,
2Department of Molecular Pharmacology and Experimental Therapeutics, and
3Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Address correspondence to: Jan M. van Deursen, 200 1st St. SW, Rochester MN 55902, USA. Phone: 507.284.8417; Email: vandeursen.jan@mayo.edu.
Find articles by van Deursen, J. in: JCI | PubMed | Google Scholar
First published April 2, 2018 - More info
J Clin Invest. 2018;128(4):1217–1228. https://doi.org/10.1172/JCI95146.
Copyright © 2018, American Society for Clinical Investigation
Cellular senescence, a major tumor-suppressive cell fate, has emerged from humble beginnings as an in vitro phenomenon into recognition as a fundamental mechanism of aging. In the process, senescent cells have attracted attention as a therapeutic target for age-related diseases, including cardiovascular disease (CVD), the leading cause of morbidity and mortality in the elderly. Given the aging global population and the inadequacy of current medical management, attenuating the health care burden of CVD would be transformative to clinical practice. Here, we review the evidence that cellular senescence drives CVD in a bimodal fashion by both priming the aged cardiovascular system for disease and driving established disease forward. Hence, the growing field of senotherapy (neutralizing senescent cells for therapeutic benefit) is poised to contribute to both prevention and treatment of CVD.
- Purchase this article
- $10
- Purchasing this article will give you full access for the calendar year.
- Purchase Site Pass
- $25
- This will give you access to every article on the site for 24 hours.
- Online subscription
- $95
- Individual online subscriptions give you full online access for the calendar year.
- Print subscription
- $795
- Individual print subscriptions give you the print journal and full online access for the year.
- JCI This Month subscription
- $125
- JCI This Month is a 16- to 20-page overview of the articles published each month
- Subscribing to JCI This Month also gives subscribers full online access for the calendar year.
- *Price outside U.S. and Canada: $225.
Copyright © 2018 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)